$HLT — HOLD | 6 MONTHS THESIS

GAAP EPS $2.45 vs $2.37 (+3.6%) | Revenue: $3.3B

Expectations gap: The stock already fell ~5% premarket on the print despite the beat-and-raise, so the near-term disappointment is partly priced. What is NOT priced: (1) a 37.6x forward adjusted EPS multiple embeds roughly 10-12% long-term EPS compounding, which requires RevPAR to re-accelerate in 2027 rather than settle into the 3.0-3.5% Q4 run-rate; (2) consensus PT of ~$353-354 implies only ~3% upside, so the sell-side sees essentially no gap; (3) the market treats the $3.5B capital return as free, but it exceeds net income by ~$1.6B and is being partly debt-funded (debt $13.45B vs $12.46B at YE25, net leverage ~3.1x), so buyback-driven EPS growth is lower quality than it appears. Conversely, the bull gap: if Q4 prints at the high end and initial 2027 guidance lands at 4%+ RevPAR with 6-7% NUG, a 37x multiple on a franchise royalty stream with 77% margins and $3.5B of shrink can hold and the stock grinds to $360-$375. Asymmetry is roughly balanced: ~8-10% to the bull case versus ~15-20% to a de-rating toward 30-32x if 2027 guidance disappoints.

Business quality: 9/10

Valuation: At $342.375 (market cap ~$79.2B on ~225M shares): ~37.6x FY26 adjusted EPS of $9.07-$9.13; ~22.5x FY26 adjusted EBITDA of $4.06-$4.08B on an EV of ~$91.8B (net debt ~$12.6B = $13.45B debt less ~$0.83B cash); ~2.4-2.6% free cash flow yield; ~41x trailing net income of ~$1.92B. Peer context: asset-light franchise royalty models (MAR, H, CHH) generally trade 18-24x EV/EBITDA and 25-33x forward EPS; HLT sits at the top of that band, and its own PE percentile vs Consumer Discretionary is 72nd, i.e., a premium to an already-cheap sector. Underlying growth justifies a premium but not an expanding one: 6.0-6.5% net unit growth, pipeline +5%, mid-single-digit RevPAR, ~10-13% EBITDA growth. Fair value range on 33-35x FY26 EPS is ~$300-$320; on 37-39x with 2027 EPS of ~$10.10-$10.30 it is ~$355-$375. That brackets the current price — no margin of safety either way. Valuation is full but not egregious; the risk is multiple compression from 37.6x toward 33x, worth roughly -$40 to -$50/share.

Reference class: Asset-light global lodging franchisors and hotel C-corps with royalty-like fee streams: Marriott (MAR), Hyatt (H), Choice Hotels (CHH); also cross-checked against premium franchise compounders (McDonald's, Domino's) for the multiple-on-fee-stream framework.

Catalyst: Primary: Q4/FY26 earnings in February 2027, which will include initial 2027 guidance — the key test is whether FY27 RevPAR guidance lands at 4%+ with net unit growth of 6-7%, or slips to low-single-digit. Secondary: Q4 (Dec) RevPAR printing at 3.0-3.5% versus Q3's 5.8%, weekly US RevPAR/STR data through the winter, MEA and APAC trends (Q3 -5.6% and -0.5% respectively), Nasdaq listing transition effective November 5, 2026 (non-fundamental), and any sell-side estimate revisions post-print. Metric to watch: adjusted EBITDA margin (77% in Q3) and management/franchise fee growth (franchise fees +10.3%, base management fees only +3.2%). Failure mode: FY27 guidance below 4% RevPAR, NUG below 6%, or capital return continuing to outrun free cash flow and pushing net leverage above ~3.5x.

Sizing: 0% — no position in either direction. Watchlist only. If a new entry materializes on a pullback into the $295-$315 zone (33-35x FY26 EPS) with stable RevPAR, initiate at 2-3% NAV; if instead the stock breaks to new highs above ~$365 after a strong 2027 guide, treat any long as a 1% momentum starter, not a value position. Do not short a 77%-margin franchise with a $3.5B buyback.

Invalidation: For the Hold stance: a decisive break below ~$315 (roughly 34-35x FY26 EPS) on no fundamental deterioration would shift the risk/reward toward Buy (thesis-invalidating for neutral) and warrant initiating a long with a stop under ~$295. Conversely, sustained trade above ~$375 on unchanged estimates would mean a 41x+ multiple on decelerating RevPAR — that would justify moving to Sell/Underweight, since it would price in an acceleration the Q4 guide does not support. Hard fundamental invalidators: FY27 RevPAR guidance below 3.5%, net unit growth below 6%, EBITDA margin falling below ~75%, or net leverage rising above ~3.5x as buybacks are debt-funded.

Hold — high-quality business, full price, no edge. HLT beat Q3 FY26 on adjusted EPS ($2.45 vs ~$2.36), grew adjusted EBITDA 8.4% to $1.058B at a 77% margin, posted 5.8% currency-neutral RevPAR and 6.0% net unit growth with a 543,100-room pipeline, and raised FY26 guidance to $9.07-$9.13 EPS and 4.0-4.5% RevPAR. But revenue of $3.33B missed by 1.8%, Q4 guidance implies RevPAR deceleration to 3.0-3.5% and EPS of $2.32-$2.38, and the stock still fell ~5% on the print. At $342.375 the shares sit at ~37.6x FY26 adjusted EPS and ~22.5x EV/EBITDA with ~3.1x net leverage and a $3.5B capital return that exceeds net income — the multiple already pays for the quality. Consensus targets near $353-354 offer ~3% upside, and the quant model is a 24th percentile sector laggard with a -0.1% expected 6-month return. Long risk/reward is roughly balanced (~8-10% upside to $360-$375 versus 15-20% downside to 33x, ~$300-$315) and short risk is unattractive against a ~4.4%-of-market-cap annual buyback. Watchlist HLT with two triggers: buy a pullback into $295-$315 (stop $295-ish below that zone, target $360-$375, ~2:1 or better), or reassess to Underweight above ~$375 if RevPAR keeps decelerating. Next hard catalyst: Q4/FY26 results and initial 2027 guidance in February 2027.